[{"id":"1eccb30a-8ad1-4c26-a948-9dcc1f4fa1f2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03832855","created_at":"2021-01-18T18:55:29.583Z","updated_at":"2025-02-25T12:27:07.330Z","phase":"Phase 1","brief_title":"Assessing the Immunogenicity of pING-hHER3FL","source_id_and_acronym":"NCT03832855","lead_sponsor":"Herbert Lyerly","biomarkers":" ERBB3","pipe":" | ","alterations":" ERBB3 expression","tags":["ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ERBB3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pING-hHER3FL"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2025-02-24"},{"id":"ac428d9a-273b-4d56-88c0-0d08a880a183","acronym":"TUXEDO-3","url":"https://clinicaltrials.gov/study/NCT05865990","created_at":"2024-01-16T19:18:52.062Z","updated_at":"2024-07-02T16:35:03.380Z","phase":"Phase 2","brief_title":"HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease","source_id_and_acronym":"NCT05865990 - TUXEDO-3","lead_sponsor":"MedSIR","biomarkers":" HER-2 • ER • PGR • ERBB3 • TACSTD2","pipe":" | ","alterations":" HER-2 positive • EGFR mutation • HER-2 expression • EGFR T790M • ERBB3 expression • TROP2 expression • ER expression • PGR expression","tags":["HER-2 • ER • PGR • ERBB3 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • EGFR mutation • HER-2 expression • EGFR T790M • ERBB3 expression • TROP2 expression • ER expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e patritumab deruxtecan (U3-1402)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 11/24/2023","start_date":" 11/24/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-05-16"},{"id":"b43bd831-d20e-49e4-b923-6ad5ee195cf2","acronym":"","url":"https://clinicaltrials.gov/study/NCT06361940","created_at":"2024-04-12T13:45:06.917Z","updated_at":"2024-07-02T16:35:09.622Z","phase":"Phase 2","brief_title":"Molecular Analyses to Identify Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer","source_id_and_acronym":"NCT06361940","lead_sponsor":"Medical College of Wisconsin","biomarkers":" EGFR • HER-2 • ERBB3 • ERBB4","pipe":" | ","alterations":" ERBB3 expression • ERBB4 expression","tags":["EGFR • HER-2 • ERBB3 • ERBB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ERBB3 expression • ERBB4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 08/01/2024","start_date":" 08/01/2024","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2024-04-15"},{"id":"1ecc2351-4f08-4e50-b996-5f839a75ff4c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04699630","created_at":"2021-01-19T20:50:12.272Z","updated_at":"2024-07-02T16:35:22.414Z","phase":"Phase 2","brief_title":"A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer","source_id_and_acronym":"NCT04699630","lead_sponsor":"SCRI Development Innovations, LLC","biomarkers":" ER • ERBB3","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • HER-2 expression • ERBB3 expression","tags":["ER • ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • HER-2 expression • ERBB3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e patritumab deruxtecan (U3-1402)"],"overall_status":"Recruiting","enrollment":" Enrollment 121","initiation":"Initiation: 05/03/2021","start_date":" 05/03/2021","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-01-24"},{"id":"5b010b67-89ab-4594-ae10-5083f9c9c6fe","acronym":"VALENTINE","url":"https://clinicaltrials.gov/study/NCT05569811","created_at":"2022-10-06T13:55:50.127Z","updated_at":"2024-07-02T16:35:36.270Z","phase":"Phase 2","brief_title":"NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial","source_id_and_acronym":"NCT05569811 - VALENTINE","lead_sponsor":"SOLTI Breast Cancer Research Group","biomarkers":" HER-2 • ER • PGR • ERBB3","pipe":" | ","alterations":" ER positive • HER-2 negative • ERBB3 expression • PGR positive","tags":["HER-2 • ER • PGR • ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ERBB3 expression • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • doxorubicin hydrochloride • cyclophosphamide • letrozole • epirubicin • patritumab deruxtecan (U3-1402)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 11/25/2022","start_date":" 11/25/2022","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 07/31/2030","study_completion_date":" 07/31/2030","last_update_posted":"2023-09-21"},{"id":"80825c94-3674-4a81-9512-e0927059f4a5","acronym":"SOLTI TOT-HER3","url":"https://clinicaltrials.gov/study/NCT04610528","created_at":"2021-01-19T20:32:21.175Z","updated_at":"2024-07-02T16:35:44.805Z","phase":"Phase 1","brief_title":"A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression","source_id_and_acronym":"NCT04610528 - SOLTI TOT-HER3","lead_sponsor":"SOLTI Breast Cancer Research Group","biomarkers":" HER-2 • ER • ERBB3","pipe":" | ","alterations":" ER positive • HER-2 negative • ERBB3 expression","tags":["HER-2 • ER • ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ERBB3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e patritumab deruxtecan (U3-1402)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 12/22/2020","start_date":" 12/22/2020","primary_txt":" Primary completion: 01/30/2022","primary_completion_date":" 01/30/2022","study_txt":" Completion: 09/30/2023","study_completion_date":" 09/30/2023","last_update_posted":"2023-06-23"},{"id":"9cf35a0d-6589-4c60-9d42-5fee66ab236e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05769764","created_at":"2023-03-15T14:02:25.719Z","updated_at":"2024-07-02T16:35:50.990Z","phase":"","brief_title":"A Study of Prevalence of HER3 Expression in Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05769764","lead_sponsor":"Daiichi Sankyo, Inc.","biomarkers":" KRAS • ALK • ERBB3","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • KRAS G12C • EGFR exon 20 insertion • ERBB3 expression • KRAS G12 • EGFR exon 20 mutation • ERBB3 mutation","tags":["KRAS • ALK • ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • KRAS G12C • EGFR exon 20 insertion • ERBB3 expression • KRAS G12 • EGFR exon 20 mutation • ERBB3 mutation"],"overall_status":"Completed","enrollment":" Enrollment 225","initiation":"Initiation: 12/19/2022","start_date":" 12/19/2022","primary_txt":" Primary completion: 04/06/2023","primary_completion_date":" 04/06/2023","study_txt":" Completion: 04/06/2023","study_completion_date":" 04/06/2023","last_update_posted":"2023-04-10"},{"id":"ca5731f4-d6d7-4d7f-a3e2-390ca029a12d","acronym":"CRUKD/22/002","url":"https://clinicaltrials.gov/study/NCT05057013","created_at":"2021-09-27T12:52:51.886Z","updated_at":"2024-07-02T16:35:52.785Z","phase":"Phase 1/2","brief_title":"HMBD-001 in Advanced HER3 Positive Solid Tumours","source_id_and_acronym":"NCT05057013 - CRUKD/22/002","lead_sponsor":"Cancer Research UK","biomarkers":" ERBB3 • NRG1","pipe":" | ","alterations":" ERBB3 expression • RAS wild-type • NRG1 fusion • ERBB3 overexpression","tags":["ERBB3 • NRG1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ERBB3 expression • RAS wild-type • NRG1 fusion • ERBB3 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HMBD-001"],"overall_status":"Recruiting","enrollment":" Enrollment 135","initiation":"Initiation: 11/10/2021","start_date":" 11/10/2021","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2023-03-21"},{"id":"e87aedf6-d57c-48bd-b9d5-e959819f1c59","acronym":"","url":"https://clinicaltrials.gov/study/NCT02345174","created_at":"2021-01-18T11:09:08.618Z","updated_at":"2024-07-02T16:37:02.615Z","phase":"Phase 1","brief_title":"Immuno Positron Emission Tomography Study of GSK2849330 in Subjects With Human Epidermal Growth Factor Receptor 3-Positive Solid Tumors","source_id_and_acronym":"NCT02345174","lead_sponsor":"GlaxoSmithKline","biomarkers":" ERBB3","pipe":" | ","alterations":" ERBB3 expression","tags":["ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ERBB3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GSK2849330"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 03/19/2015","start_date":" 03/19/2015","primary_txt":" Primary completion: 06/02/2016","primary_completion_date":" 06/02/2016","study_txt":" Completion: 06/02/2016","study_completion_date":" 06/02/2016","last_update_posted":"2019-02-21"},{"id":"d0a26368-3c02-4fa9-b61e-1255df965ddd","acronym":"","url":"https://clinicaltrials.gov/study/NCT03499626","created_at":"2021-01-18T17:13:41.549Z","updated_at":"2024-07-02T16:37:11.507Z","phase":"Phase 1b","brief_title":"Phase 1b of ASLAN001 (Varlitinib) in Patients With Advanced/ Metastatic Hepatocellular Carcinoma (HCC)","source_id_and_acronym":"NCT03499626","lead_sponsor":"National University Hospital, Singapore","biomarkers":" ERBB3","pipe":" | ","alterations":" ERBB3 expression","tags":["ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ERBB3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • Lenvima (lenvatinib) • varlitinib (ASLAN001)"],"overall_status":"Unknown status","enrollment":" Enrollment 22","initiation":"Initiation: 05/05/2017","start_date":" 05/05/2017","primary_txt":" Primary completion: 05/05/2019","primary_completion_date":" 05/05/2019","study_txt":" Completion: 05/05/2021","study_completion_date":" 05/05/2021","last_update_posted":"2018-04-17"},{"id":"39b75b55-ad92-4eb5-b91c-32fcb9289773","acronym":"","url":"https://clinicaltrials.gov/study/NCT01482377","created_at":"2021-01-18T06:11:26.844Z","updated_at":"2024-07-02T16:37:26.198Z","phase":"Phase 1a/1b","brief_title":"A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin","source_id_and_acronym":"NCT01482377","lead_sponsor":"Hoffmann-La Roche","biomarkers":" EGFR • ERBB3","pipe":" | ","alterations":" EGFR expression • ERBB3 expression • EGFR positive","tags":["EGFR • ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • ERBB3 expression • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • erlotinib • lumretuzumab (RG7116)"],"overall_status":"Completed","enrollment":" Enrollment 145","initiation":"Initiation: 12/01/2011","start_date":" 12/01/2011","primary_txt":" Primary completion: 02/01/2016","primary_completion_date":" 02/01/2016","study_txt":" Completion: 02/01/2016","study_completion_date":" 02/01/2016","last_update_posted":"2017-01-27"}]